Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-05-16
2006-05-16
Qazi, Sabiha (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S169000, C514S177000, C514S178000, C514S180000
Reexamination Certificate
active
07045513
ABSTRACT:
Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation comprises, in solid form, DHEA, at least 85% of which is present as a single polymorph selected from the form I polymorph or the form II polymorph, and at least one pharmaceutical excipient. Methods for making and using such compositions are also disclosed.
REFERENCES:
patent: 5077284 (1991-12-01), Loria et al.
patent: 5407927 (1995-04-01), Morales et al.
patent: 5728688 (1998-03-01), Labrie
patent: 5776923 (1998-07-01), Labrie
patent: 5780460 (1998-07-01), Labrie
patent: 5824671 (1998-10-01), Labrie
patent: 5837700 (1998-11-01), Labrie
patent: 0389035 (1990-03-01), None
patent: 0389035 (1990-09-01), None
Chang et al. (DN 123:265915, HCAPLUS, abstract of J. Pharm. Sci. (1995), 84(10), 1169-79).
Chang, Luh-Chian et al., “Solid State Characterization of Dehydroepiandrosterone,” Journal of Pharmaceutical Sciences 84:10:1169-1179 (Oct. 1995).
Yu, Lian et al., “Physical Characterization of Polymorphic Drugs: An Integrated Characterization Strategy,” PSTT 1:3:118-127 (Jun. 1998).
Merck: “The Merck Index,” USA XP002148233, p. 1323 (1996).
Arit, W., et al.,J. Clin. Endocrinol. Metab. 83(6):1928-1934 (1998).
Barker, E.V. et al.,Endocrinology 134:982-989 (1994).
Barrett-Connor et al.,New Engl. J. Med. 315:1519 (1986).
Caira, M.R. et al.,J. Chem. Crystallogr. 25:393 (1995).
Chang, L.C. et al.J. Pharmaceut. Sci. 84:1169-1179 (1995).
Comer, K.A. and Falany, C.N.,Mol. Pharmacol. 41:645-651 (1992).
Cox, P.J. et al.,Acta Crystallogr.C46, 334-336 (1990).
Falany, C.N. et al.,Ann. NY Acad. Sci. 774:59-72 (1995).
Frye and Maciel,J. Mag. Res. 48:125 (1982).
Grodin, J.M. et al.,J. Clin. Endo. Metab. 36:207-214 (1973).
Lachelin, G.C. et al.,J. Clin. Endocrinol. Metab. 49(6):892-898 (1979).
Longcope, C.,Ann. NY Acad. Sci. 774:143-148 (1995).
MacDonald, J.C.J. Mag. Res.38:381 (1980).
Meikle, A.W. et al.,J. Steroid Biochem. Molec. Biol.293-304 (1992).
Merck,The Merck Index1996, Merck, NJ, USA XP002148233.
Orentreich, N. et al,J. Clin. Endocrinol. Metab. 59:551-555 (1984).
Van Cauter, E.,Horm. Res. 32(2):45-53 (1990).
Yen, S.S. et al.,Ann. NY Acad. Sci. 774: 128-142 (1995).
Yu, L. (Reprint) et al.Pharmaceutical Science&Technology Todayvol. 1., No. 3 pp. 118-127 (Jun., 1998).
Gurwith Marc J.
Parasrampuria Jagdish
Schwartz Kenneth E.
Yonker Maxine B.
Genelabs Technologies, Inc.
Haliday Emily M.
Qazi Sabiha
Quine I.P. Law Group P.C.
LandOfFree
DHEA composition and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DHEA composition and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DHEA composition and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3643459